Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) has scheduled its first quarter 2025 financial results conference call and webcast for May 7, 2025, at 8:30 a.m. ET. Investors can pre-register for the phone call, while a live audio webcast with accompanying slides will be available through the company's website under "Events and Presentations" in the "Investors and Media" section.

Apellis positions itself as a global biopharmaceutical leader that combines scientific innovation with patient care. The company has achieved significant milestones, including:

• Introduction of the first new complement medicine class in 15 years
• Two approved medicines targeting C3
• Development of the first-ever therapy for geographic atrophy, a major cause of blindness globally

The webcast replay will be accessible for 90 days after the event. Investor relations contact is available through Neil Carnahan.

Positive

• First-ever therapy for geographic atrophy approved and in market
• Two approved medicines targeting C3 in portfolio
• Pioneer in complement medicine with first new class in 15 years

Negative

• None.

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET.

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:
Neil Carnahan
neil.carnahan@apellis.com
207.318.4494

FAQ

When is Apellis Pharmaceuticals (APLS) Q1 2025 earnings call?

Apellis Pharmaceuticals (APLS) will host its Q1 2025 earnings conference call on Wednesday, May 7, 2025, at 8:30 a.m. ET.

How can investors access Apellis Pharmaceuticals (APLS) Q1 2025 earnings call?

Investors can access the call by pre-registering through the provided link or view the live audio webcast on the 'Events and Presentations' page of Apellis' website investor section.

How long will Apellis Pharmaceuticals (APLS) Q1 2025 earnings webcast be available?

The webcast replay will be available for 90 days following the May 7, 2025 earnings event.

What is Apellis Pharmaceuticals' (APLS) main medical breakthrough?

Apellis introduced the first new class of complement medicine in 15 years and developed the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide.

What therapeutic area does Apellis Pharmaceuticals (APLS) focus on?

Apellis focuses on developing complement medicines targeting C3 for challenging diseases, including treatments for geographic atrophy and other serious conditions.